Targeting histone lactylation in pancreatic ductal adenocarcinoma using RNA therapeutics: from metabolic-epigenetic mechanisms to clinical translation

Pancreatic ductal adenocarcinoma (PDAC) is among the most treatment-resistant malignancies because of its dense desmoplastic stroma, metabolic plasticity, and immunosuppressive tumor microenvironment. Lactate, once viewed primarily as a glycolytic byproduct, also acts as an epigenetic signal through histone lactylation, particularly histone H3 lysine 18 lactylation (H3K18la). Recent PDAC studies implicate H3K18la in three distinct reported mechanisms: a glycolysis-H3K18la-TTK/BUB1B positive-feedback loop, an H3K18la-ACAT2-cholesterol axis that promotes macrophage-mediated immunosuppression, and a PCAF-H3K18la-CXCL1 pathway that recruits neutrophils and supports immune escape. Together, these findings identify the lactate-lactylation axis as a potential therapeutic vulnerability in PDAC. This review synthesizes evidence linking lactate metabolism, histone lactylation, immune remodeling, and therapeutic resistance, with emphasis on RNA-based interventions. We evaluate small interfering RNA, microRNA-based, antisense, and other non-coding RNA strategies directed at lactate production and transport, chromatin writers and erasers, and axis-specific effectors. We also examine translational barriers, including nuclease degradation, renal clearance, membrane impermeability, endosomal trapping, off-target effects, and limited penetration of nanoparticles through the PDAC stroma. Integrating cancer metabolism, epigenetics, immunology, and RNA nanomedicine, this review proposes a translational framework for testing lactylation-directed RNA therapeutics in PDAC.

Authors

Institutions

Publication Details

Journal
Frontiers in Drug Discovery
Published
2026-11-16
DOI
https://doi.org/10.3389/fddsv.2026.2004992
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting histone lactylation in pancreatic ductal adenocarcinoma using RNA therapeutics: from metabolic-epigenetic mechanisms to clinical translation

Muhammad Imran Sajid, Muhammad Eshan, Syeda Nazish Sohaib, Emma Niskanen et al.
4 links
Frontiers in Drug Discovery
Pancreatic and Hepatic Oncology Research
article

Targeting histone lactylation in pancreatic ductal adenocarcinoma using RNA therapeutics: from metabolic-epigenetic mechanisms to clinical translation

Muhammad Imran Sajid, Muhammad Eshan, Syeda Nazish Sohaib, Emma Niskanen, Faryal Fatima, Kashaf Noor Babar, Keykavous Parang, Rakesh Kumar Tiwari, Muhammad Mudassar Wakil, Elena Chavez
article en

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the most treatment-resistant malignancies because of its dense desmoplastic stroma, metabolic plasticity, and immunosuppressive tumor microenvironment. Lactate, once viewed primarily as a glycolytic byproduct, also acts as an epigenetic signal through histone lactylation, particularly histone H3 lysine 18 lactylation (H3K18la). Recent PDAC studies implicate H3K18la in three distinct reported mechanisms: a glycolysis-H3K18la-TTK/BUB1B positive-feedback loop, an H3K18la-ACAT2-cholesterol axis that promotes macrophage-mediated immunosuppression, and a PCAF-H3K18la-CXCL1 pathway that recruits neutrophils and supports immune escape. Together, these findings identify the lactate-lactylation axis as a potential therapeutic vulnerability in PDAC. This review synthesizes evidence linking lactate metabolism, histone lactylation, immune remodeling, and therapeutic resistance, with emphasis on RNA-based interventions. We evaluate small interfering RNA, microRNA-based, antisense, and other non-coding RNA strategies directed at lactate production and transport, chromatin writers and erasers, and axis-specific effectors. We also examine translational barriers, including nuclease degradation, renal clearance, membrane impermeability, endosomal trapping, off-target effects, and limited penetration of nanoparticles through the PDAC stroma. Integrating cancer metabolism, epigenetics, immunology, and RNA nanomedicine, this review proposes a translational framework for testing lactylation-directed RNA therapeutics in PDAC.

Frontiers in Drug DiscoveryVol. 6
University of Lahore (PK), Chapman University (US), Riphah International University (PK), University of Pavia (IT), Western University of Health Sciences (US)
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon